Single nucleotide polymorphism of AGT rs699 in the pathogenesis of hypertension and ACE inhibitors response: a narrative review
Abstract
Hypertension is a chronic cardiovascular disease that affects more than one billion people in the world. Angiotensinogen in the renin-angiotensin-aldosterone system (RAAS) is the main precursor encoded by angiotensinogen (AGT) gene and plays an important role in the development of hypertension. Single nucleotide polymorphism (SNP) of AGT gene is thought related to the pathogenesis of hypertension and angiotensinogen levels in plasma that may affect response to ACE inhibitors. This article reviewed the association of SNP AGT rs699 with the pathogenesis of hypertension and ACE inhibitors response. A total of 14 articles published from 1995 to 2023 were collected from databases including NCBI, Google Scholar, PubMed and Science Direct. Several studies in different populations have been conducted and showed various results. The T allele or TT genotype of AGT rs699 was associated in the pathogenesis of hypertension. However, the association between AGT rs699 and ACE inhibitor response shows inconsistent results, thus further research is needed.
References
DiPiro JT, editor. Pharmacotherapy: a pathophysiologic approach. Eleventh edition. New York: McGraw Hill Medical; 2020.
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; 41(12):1874-2071
https://doi.org/ 10.1097/HJH.0000000000003621. PMID: 37345492.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet Lond Engl. 2021;398(10304):957-80.
https://doi.org/10.1016/S0140-6736(22)00061-7.
WHO. Guideline for the pharmacological treatment of hypertension in adults. World Health Organization; 2021.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. 2020;
https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Martyniak A, Tomasik PJ. A new perspective on the renin-angiotensin system. diagnostics. 2023;13(1):16.
https://doi.org/10.3390/diagnostics13010016
Kahlon T, Carlisle S, Otero Mostacero D, Williams N, Trainor P, DeFilippis AP. Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics. JACC Heart Fail 2022;10(10):699-713.
https://doi.org/10.1016/j.jchf.2022.06.005
Kolovou V, Lagou E, Mihas C, Giannakopoulou V, Katsiki N, Kollia A, et al. Angiotensinogen (AGT) M235T, AGT T174M and angiotensin-1- converting enzyme (ACE) I/D gene polymorphisms in essential hypertension: effects on ramipril efficacy. Open Cardiovasc Med J 2015;9(1):118-26.
https://doi.org/10.2174/1874192401509010118
Fajar JK, Pikir BS, Sidarta EP, Saka PNB, Akbar RR, Tamara F, et al. The genes polymorphism of angiotensinogen (AGT) M235T and AGT T174M in patients with essential hypertension: A meta-analysis. Gene Rep 2019;16:100421.
https://doi.org/10.1016/j.genrep.2019.100421
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primer. 2018;4(1):18014.
https://doi.org/10.1038/nrdp.2018.14
Flaten HK, Monte AA. The pharmacogenomic and metabolomic predictors of ace inhibitor and angiotensin II receptor blocker effectiveness and safety. Cardiovasc Drugs Ther 2017;31(4):471-82.
https://doi.org/10.1007/s10557-017-6733-2
Lu H, Cassis LA, Kooi CWV, Daugherty A. Structure and functions of angiotensinogen. Hypertens Res. 2016;39(7):492-500.
https://doi.org/10.1038/hr.2016.17
Liau Y, Chua I, Kennedy MA, Maggo S. Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema. Clin Exp Allergy 2019;49(2):142-54.
https://doi.org/10.1111/cea.13326
Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80(8):797-811.
https://doi.org/10.1007/s40265-020-01290-3
Melake A, Alemu M, Berhane N. Association between angiotensinogen M235T gene polymorphism and risk of hypertension: a case control study among Ethiopian patients. Ethiop Med J [Internet]. 2023 [cited 2023 Jul 23];61(2). Available from: https://www.ajol.info/index.php/emj/article/view/249955
Shahid M, Rehman K, Akash MSH, Suhail S, Kamal S, Imran M, et al. Genetic polymorphism in angiotensinogen and its association with cardiometabolic diseases. Metabolites 2022;12(12):1291.
https://doi.org/10.3390/metabo12121291
Makuc J, Šeruga M, Završnik M, Cilenšek I, Petrovič D. Angiotensinogen (AGT) gene missense polymorphisms (rs699 and rs4762) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus. Bosn J Basic Med Sci 2017;17(3):262-7.
https://doi.org/10.17305/bjbms.2017.1823
Kooffreh ME, Anumudu CI, Akpan EE, Ikpeme EV, Lava Kumar P. A study of the M235T variant of the angiotensinogen gene and hypertension in a sample population of Calabar and Uyo, Nigeria. Egypt J Med Hum Genet 2013;14(1):13-9.
https://doi.org/10.1016/j.ejmhg.2012.06.007
Abramovs N, Brass A, Tassabehji M. Hardy-Weinberg Equilibrium in the Large Scale Genomic Sequencing Era. Front Genet [Internet]. 2020 [cited 2023 Jul 24];11. Available from: https://www.frontiersin.org/articles/10.3389/fgene.2020.00210
https://doi.org/10.3389/fgene.2020.00210
Shamaa MM, Fouad H, Haroun M, Hassanein M, Hay MAA. Association between the Angiotensinogen (AGT) gene (M235T) polymorphism and Essential Hypertension in Egyptian patients. Egypt Heart J 2015;67(1):1-5.
https://doi.org/10.1016/j.ehj.2013.10.001
Karthikeyan M, Singh K, Rose R. Angiotensin gene polymorphisms (T174M and M235T) are significantly associated with the hypertensive patients of Tamil Nadu, South India. Int J Hum Genet 2013;13:201-7.
https://doi.org/10.1080/09723757.2013.11886218
Sari ANP, Pratamawati TM. Hubungan polimorfisme M235T gen AGT dengan inflamasi pembuluh darah pada pasien hipertensi esensial. Tunas Med J Kedokt Kesehat 2022;8(2).
Sandar Oo K, Khin W, Han S, Tun H. Association between angiotensinogen gene M235T polymorphism and plasma angiotensinogen level in essential hypertension. J Hypertens 2017; 6:3 (Suppl)
https://doi.og/10.4171/2167-1095-C1-003
Srivastava K, Chandra S, Bhatia J, Narang R, Saluja D. Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (enalapril). J Pharm Pharm Sci 2012;15(3):399.
https://doi.org/10.18433/J3KW3B
Angst P, Ameline C, Haag CR, Ben-Ami F, Ebert D, Fields PD. Genetic drift shapes the evolution of a highly dynamic metapopulation. Mol Biol Evol. 2022; 39(12):msac264.
https://doi.org/10.1093/molbev/msac264
Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens. 1995;13(12 Pt 2):1602-9.
https://doi.org/10.1097/00004872-199512010-00017
Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin ii receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007;115(6):725-32.
https://doi.org/10.1161/CIRCULATIONAHA.106.642058
Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996;14(2):259-62.
https://doi.org/10.1097/00004872-199602000-00016
Toyofyuku M, Imazu M, Sumii K, Yamamoto H, Hayashi Y, Hiyama K, et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis 2002; 160(2):339-44.
https://doi.org/10.1016/S0021-9150(01)00592-5
Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16(12):1011-7.
https://doi.org/10.1016/j.amjhyper.2003.07.018
Yu H min, Lin S guang, Zhang Y qing, Ma W jun, Liu G zhang. [The AGT genotype affects the antihypertensive effects of benazepril]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Sep;33(9):819-23.
Singh KhD, Jajodia A, Kaur H. Gender Specific Association of RAS Gene polymorphism with essential hypertension: a case-control study. BioMed Res Int 2014;
https://doi.org/10.1155/2014/53805
Repchuk Y, Sydorchuk LP, Sydorchuk AR, Fedonyuk LY, Kamyshnyi O, Korovenkova O, et al. Linkage of blood pressure, obesity and diabetes mellitus with angiotensinogen gene (AGT 704T>C/rs699) polymorphism in hypertensive patients. Bratisl Med J. 2021;122(10):715-20.
